ALC vs GSK
Alcon Inc vs GSK plc — AI-powered side-by-side comparison
VS
GSK
GSK plc
64
Insufficient Data
| Metric | ALC | GSK |
|---|
| AI Score |
68
|
64
|
| Price |
$75.39
|
$50.91
|
| P/E Ratio |
45.39×
|
15.80×
|
| ROE |
4.4%
|
35.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
73.3%
|
| Debt / Equity |
0.24×
|
1.03×
|
| Dividend Yield |
0.5%
|
3.5%
|
| RSI (14) |
73.4
|
39.2
|
| Beta |
0.703
|
0.3
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus GSK.
ALC leads by 4 points.
ALC scores 68/100 (Buy) versus GSK at 64/100 (Insufficient Data).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
GSK Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical